Introduction to the properties and uses of the drug Atrasentan

Atrasentan is an endothelin receptor A (ETA) selective antagonist that has attracted much attention internationally. It is a small molecule drug targeting the inflammation and fibrosis pathways of kidney disease. It is not a traditional immunosuppressant, nor is it an antihypertensive drug. Instead, it uses the "anti-endothelin-1 pathway" as a key point of action in the renal pathological mechanism, thereby reducing proteinuria, lowering glomerular pressure, and delaying the progression of kidney disease. Its most important and clearest indication is to treat primary immunoglobulin A nephropathy (IgAN) and help reduce urinary protein levels.

IgA nephropathy is a chronic kidney disease in which immune complex deposition leads to glomerular structural damage. Persistent proteinuria and elevated glomerular pressure are the core factors promoting deterioration. By blocking ETA receptors, Atrasentan reduces the vasoconstriction, inflammatory factor release and fibrosis reaction triggered by endothelin-1, allowing the glomerulus to operate in a "low pressure" state, thereby reducing protein leakage. This mechanism of action is complementary to traditional RAS blocking drugs, so in the clinical pathways of some countries, atrasentan is often used in patients with uncontrolled persistent proteinuria.

Unlike immunosuppressive therapy, atrasentan does not change disease progression by suppressing the immune system, but intervenes based on the regulatory mechanism of vasoactivity and fibrosis. Therefore, the side effects are more likely to be symptoms related to body fluid retention such as edema, blood pressure changes, or weight gain, which are closely related to its pharmacological properties. For this reason, in actual use, doctors will closely monitor water and sodium retention and individualize the dosage according to the patient's renal function and underlying diseases.

The value of atrasentan lies in its dual role of "reducing proteinuria and delaying the deterioration of renal function". It is especially suitable for adult patients with IgA nephropathy whose proteinuria continues to increase and traditional treatments are insufficient.

Reference materials:https://www.vanrafia.com/